Reported 1 day ago
Merck & Co. (MRK) has announced the dosing of the first patient in its HERTHENA-Breast04 phase 3 trial, which aims to assess the efficacy and safety of patritumab deruxtecan in treating patients with advanced hormone receptor-positive, HER2-negative breast cancer. This drug, developed in collaboration with Daiichi Sankyo, targets specific cancer treatments following previous therapies.
Source: YAHOO